Webinar: ALS Clinical Trial Pipeline Series - Winter 2019

ALS Study, Sanguine PT1

ALS Study, Sanguine PT2

ALS Platform Trial

Press Release: https://www.massgeneral.org/about/pressrelease.aspx?id=2454 

Webinar: https://www.neals.org/for-people-with-als-caregivers/educational-webinars/accelerating-therapy-development-and-expanding-access

List of sites participating: https://www.massgeneral.org/neurology/als/research/platform-trial-sites 

Various trials run by Dr. Richard Bedlack at Duke University:

• News Story: https://www.msn.com/en-us/health/wellness/duke-university-hospital-slated-to-start-als-clinical-trials-before-the-end-of-the-year/vi-BBWF6G1 

• Webinar: https://www.neals.org/for-people-with-als-caregivers/educational-webinars/postcards-from-the-edge-updates-on-six-unusual-als-projects

Greetings ALS Community,

Today we have hopeful news to share on this MGH ALS Link - the kind of news we have been working together as a community to create for many years. 
The recent CENTAUR Trial of AMX0035 has released results showing a significant slowing of ALS in people taking this drug in trial. Click here to read the Amylyx Pharmaceuticals press release.
The trial was led by Dr. Sabrina Paganoni and our coordination center here at the Healey Center for ALS at Mass General, sponsored by Amylyx Pharmaceuticals and enrolled People with ALS across the country as part of the Northeast ALS Consortium, including at MGH. 
We know this will raise many practical questions about next steps. These results are just being released today, so we do not have all the answers to these questions yet.  We will send out more information as soon as it is available

Best,

Your Team at the Healey Center for ALS at MGH